107 related articles for article (PubMed ID: 15845683)
21. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
23. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.
Mirghani RA; Hellgren U; Westerberg PA; Ericsson O; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1999 Nov; 66(5):454-60. PubMed ID: 10579472
[TBL] [Abstract][Full Text] [Related]
24. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans.
Becquemont L; Ragueneau I; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P
Clin Pharmacol Ther; 1997 Jun; 61(6):619-27. PubMed ID: 9209244
[TBL] [Abstract][Full Text] [Related]
25. Effects of CYP3A inhibition on the metabolism of cilostazol.
Suri A; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():61-8. PubMed ID: 10702888
[TBL] [Abstract][Full Text] [Related]
26. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
[TBL] [Abstract][Full Text] [Related]
27. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
[TBL] [Abstract][Full Text] [Related]
28. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
29. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.
Rasmussen BB; Jeppesen U; Gaist D; Brøsen K
Ther Drug Monit; 1997 Feb; 19(1):56-62. PubMed ID: 9029748
[TBL] [Abstract][Full Text] [Related]
30. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
Culm-Merdek KE; von Moltke LL; Harmatz JS; Greenblatt DJ
Br J Clin Pharmacol; 2005 Nov; 60(5):486-93. PubMed ID: 16236038
[TBL] [Abstract][Full Text] [Related]
31. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
32. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.
Yasui N; Otani K; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1996 May; 59(5):514-9. PubMed ID: 8646822
[TBL] [Abstract][Full Text] [Related]
33. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.
Yao C; Kunze KL; Kharasch ED; Wang Y; Trager WF; Ragueneau I; Levy RH
Clin Pharmacol Ther; 2001 Nov; 70(5):415-24. PubMed ID: 11719727
[TBL] [Abstract][Full Text] [Related]
34. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
35. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.
Jerling M; Lindström L; Bondesson U; Bertilsson L
Ther Drug Monit; 1994 Aug; 16(4):368-74. PubMed ID: 7974626
[TBL] [Abstract][Full Text] [Related]
36. Effect of fluvoxamine on the pharmacokinetics of quinidine.
Damkier P; Hansen LL; Brøsen K
Eur J Clin Pharmacol; 1999 Aug; 55(6):451-6. PubMed ID: 10492058
[TBL] [Abstract][Full Text] [Related]
37. A fluvoxamine-caffeine interaction study.
Jeppesen U; Loft S; Poulsen HE; Brśen K
Pharmacogenetics; 1996 Jun; 6(3):213-22. PubMed ID: 8807660
[TBL] [Abstract][Full Text] [Related]
38. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
de Weger VA; Goel S; von Moos R; Schellens JHM; Mach N; Tan E; Anand S; Scott JW; Lassen U
Cancer Chemother Pharmacol; 2018 Jan; 81(1):73-80. PubMed ID: 29101463
[TBL] [Abstract][Full Text] [Related]
39. Metabolism and elimination of quinine in healthy volunteers.
Mirghani RA; Hellgren U; Bertilsson L; Gustafsson LL; Ericsson O
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):423-7. PubMed ID: 12920491
[TBL] [Abstract][Full Text] [Related]
40. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.
Lamberg TS; Kivistö KT; Laitila J; Mårtensson K; Neuvonen PJ
Eur J Clin Pharmacol; 1998; 54(9-10):761-6. PubMed ID: 9923581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
